Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OXYZEN 369
- Development stage
- Unknown
- Lead developer
- Symbiosis Labs
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
OXYZEN 369 is a dietary supplement developed and marketed by Symbiosis Labs, an Indian pharmaceutical company specializing in generic and nutraceutical products. The formulation is a combination of Omega-3, Omega-6, and Omega-9 fatty acids, typically derived from botanical sources such as flaxseed oil. These fatty acids are essential for maintaining cell membrane integrity, supporting cardiovascular health, and serving as precursors for the synthesis of anti-inflammatory eicosanoids. The product is positioned as a wellness supplement to support heart, brain, and skin health within the Indian market. As a nutraceutical, it is commercially available and does not follow the traditional clinical trial pathway required for prescription pharmaceuticals.
- Brand names
- OXYZEN 369OXYZEN369OXYZEN-369
- Other names
- Oxyzen-369Oxyzen369Oxyzen 369
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)PPARA (Peroxisome proliferator-activated receptor alpha)FFAR4 (Free fatty acid receptor 4)
Beyond the preview
Go deeper on OXYZEN 369.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OXYZEN 369.